October 11, 2021 from 11:30 CT to 12:30 CT
Did you know that C. difficile is still classified as an urgent threat by the Centers for Disease Control Prevention?
In this activity, Dr. Paul Feuerstadt and Dr. Kevin Garey will discuss community and healthcare-associated infections, recent updates to guidelines, and evidence-based selection of antimicrobial therapy for the treatment of initial infection and prevention of recurrence CDI. What happens if the patient returns with recurrence? Join us to find out as the faculty discuss a patient case highlighting the risks of recurrence and selection of therapy.
As a result of participating in this educational activity, clinicians should be able to:
- Discuss the selection of antimicrobials considerate of their impact on gut microbiota
- Interpret data on the role of antitoxins in the treatment of initial infection and prevention of recurrent CDI
- Assess available and updated clinical guidelines to ensure evidence-based therapeutic selection for treatment of initial infection and prevention of recurrent CDI
- Describe clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent difficile infection
To view the agenda and register: https://www.achlcme.org/antimicrobial-selection-cdiff-infection-mad-id
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 1.0 contact hours.
This program is developed by ACHL in collaboration with MAD-ID.
This activity is supported by an educational grant from Merck & Co., Inc.